The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of atumelnant treatment in pediatric participan…

Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia

~Estimated

~$10 – $8,750

Crinetics Pharmaceuticals Inc.NCT07159841

Phase 3

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants With Classic Congenital Adrenal Hyperplasia (Calm-CAH)

The purpose of this study is to evaluate the efficacy, safety, PK, and PD of atumelnant in adults with classic CAH due to 21-OHD.

Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia

~Estimated

~$10 – $8,750

Crinetics Pharmaceuticals Inc.NCT07144163

Phase 2

An Open-label, Long-term Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia (CALM2-CAH)

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894).

Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia

~Estimated

~$10 – $8,750

Crinetics Pharmaceuticals Inc.NCT06712823